ValuEngine upgraded shares of Diplomat Pharmacy (NYSE:DPLO) from a buy rating to a strong-buy rating in a research note released on Thursday, ValuEngine reports.
Other analysts have also issued research reports about the stock. Guggenheim started coverage on shares of Diplomat Pharmacy in a research note on Wednesday, April 17th. They set a neutral rating and a $6.00 price objective on the stock. Zacks Investment Research lowered shares of Diplomat Pharmacy from a buy rating to a hold rating in a research note on Tuesday, July 16th. Finally, Credit Suisse Group dropped their price objective on shares of Diplomat Pharmacy from $8.00 to $6.00 and set a neutral rating on the stock in a research note on Monday, April 29th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. Diplomat Pharmacy presently has an average rating of Hold and an average target price of $9.96.
Shares of DPLO traded down $0.21 during mid-day trading on Thursday, reaching $5.27. 335,170 shares of the stock traded hands, compared to its average volume of 563,020. The stock has a market cap of $393.72 million, a price-to-earnings ratio of 26.35 and a beta of 1.06. The firm has a fifty day moving average of $5.48. Diplomat Pharmacy has a 12-month low of $4.17 and a 12-month high of $21.62. The company has a current ratio of 1.00, a quick ratio of 0.66 and a debt-to-equity ratio of 1.00.
Diplomat Pharmacy (NYSE:DPLO) last posted its quarterly earnings data on Tuesday, May 7th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.26). The firm had revenue of $1.26 billion for the quarter, compared to analysts’ expectations of $1.17 billion. Diplomat Pharmacy had a negative net margin of 5.85% and a positive return on equity of 1.38%. The company’s revenue for the quarter was down 6.4% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.01) EPS. As a group, research analysts predict that Diplomat Pharmacy will post -0.55 earnings per share for the current year.
Several large investors have recently modified their holdings of DPLO. Swiss National Bank raised its stake in Diplomat Pharmacy by 20.3% during the second quarter. Swiss National Bank now owns 110,800 shares of the company’s stock worth $675,000 after acquiring an additional 18,700 shares in the last quarter. Stephens Inc. AR raised its stake in Diplomat Pharmacy by 1,482.3% during the second quarter. Stephens Inc. AR now owns 6,600,015 shares of the company’s stock worth $40,194,000 after acquiring an additional 6,182,889 shares in the last quarter. Aperio Group LLC raised its stake in Diplomat Pharmacy by 127.0% during the second quarter. Aperio Group LLC now owns 28,304 shares of the company’s stock worth $172,000 after acquiring an additional 15,834 shares in the last quarter. KBC Group NV acquired a new position in Diplomat Pharmacy during the second quarter worth $46,000. Finally, First Trust Advisors LP raised its stake in Diplomat Pharmacy by 154.6% during the first quarter. First Trust Advisors LP now owns 56,438 shares of the company’s stock worth $328,000 after acquiring an additional 34,274 shares in the last quarter. Institutional investors and hedge funds own 79.40% of the company’s stock.
About Diplomat Pharmacy
Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company operates through Specialty and PBM (pharmacy benefit management) segment. It provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.
Featured Article: How to track put option volume
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.